Targeting the TGF-β1 pathway to prevent normal tissue injury after cancer therapy

Oncologist

Volumn 15, Issue 4, 2010, Pages 350-359

  Anscher, Mitchell S ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Complications; Fibrosis; Lung cancer; Transforming growth factor

Indexed keywords

BLEOMYCIN; CYTOKINE; GEFITINIB; PROTEIN ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA1 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; ATROPHY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVOR; CANCER THERAPY; CELL LOSS; CELL PROLIFERATION; CLINICAL TRIAL; CONNECTIVE TISSUE; DRUG DOSE COMPARISON; DRUG TARGETING; EPITHELIUM CELL; FIBROSIS; HISTOPATHOLOGY; HUMAN; MOLECULAR THERAPY; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUBLIC HEALTH PROBLEM; SINGLE DRUG DOSE; THERAPY EFFECT; TISSUE INJURY; UNITED STATES; ANIMAL; DRUG EFFECT; GENE EXPRESSION REGULATION; LIVER; LUNG INJURY; METABOLISM; NEOPLASM; ONCOLOGY; PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION INJURY; RADIOTHERAPY; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER; LUNG INJURY; NEOPLASMS; RADIATION DOSAGE; RADIATION INJURIES; RADIATION ONCOLOGY; RADIOTHERAPY; RISK ASSESSMENT; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1; TRANSLATIONAL RESEARCH;

EID: 77951709927     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-S101     Document Type: Article

References (114)

1. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-122.
2. Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. Semin Radiat Oncol 2007;17: 131-140.
3. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 2005;63:5-24.
4. Kong FM, Pan C, Eisbruch A et al. Physical models and simpler dosimetric descriptors of radiation late toxicity. Semin Radiat Oncol 2007;17: 108-120.
5. Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: Mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys 2006;66:1281-1293.
6. Brush J, Lipnick SL, Phillips T et al. Molecular mechanisms of late normal tissue injury. Semin Radiat Oncol 2007;17:121-130.
7. Rodemann HP, Blaese MA. Responses of normal cells to ionizing radiation. Semin Radiat Oncol 2007;17:81-88.
8. Travis EL. Genetic susceptibility to late normal tissue injury. Semin Radiat Oncol 2007;17:149-155.
9. Anscher MS, Chen L, Rabbani Z et al. Recent progress in defining mechanisms and potential targets for prevention of normal tissue injury after radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:255-259.
10. Laiho M, Keski-Oja J. Transforming growth factors-beta as regulators of cellular growth and phenotype. Crit Rev Oncog 1992;3:1-26.
11. Massagué J, Cheifetz S, Laiho M et al. Transforming growth factor-beta. Cancer Surv 1992;12:81-103.
12. Massagué J, Blain SW, Lo RS. TGF signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
13. Lamouille S, Derynck R. Cell size and invasion in TGF--induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 2007;178:437-451.
14. Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF- family proteins in development and disease. Nat Cell Biol 2007;9:1000-1004.
15. Massagué J. TGF in Cancer. Cell 2008;134:215-230.
16. Taylor IW, Wrana JL. SnapShot: The TGF pathway interactome. Cell 2008;133:378.e1.
17. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005;23:2078-2093.
18. Chen C, Wang XF, Sun L. Expression of transforming growth factor beta (TGF) type III receptor restores autocrine TGF 1 activity in human breast cancer MCF-7 cells. J Biol Chem 1997;272:12862-12867.
19. Grady WM, Myeroff LL, Swinler SE et al. Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res 1999;59:320-324.
20. Villanueva A, Garcia C, Paules AB et al. Disruption of the antiproliferative TGF- signaling pathways in human pancreatic cancer cells. Oncogene 1998;17:1969-1978.
21. Yan Z, Deng X, Friedman E. Oncogenic Ki-ras confers a more aggressive colon cancer phenotype through modification of transforming growth factor-beta receptor III. J Biol Chem 2001;276:1555-1563.
22. Derynck R, Akhurst RJ, Balmain A. TGF- signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-129.
23. Branton MH, Kopp JB. TGF- and fibrosis. Microbes Infect 1999;1: 1349-1365.
24. Border WA, Brees D, Noble NA. Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contrib Nephrol 1994;107: 140-145.
25. Munger J, Huang X, Kawakatsu H et al. The integrin vß6 binds and activates latent TGF 1: A mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-328.
26. Lawrence D. Identification and activation of latent transforming growth factor. Methods Enzymol 1991;198:327-336.
27. Koli K, Saharinen J, Hyytiäinen M et al. Latency, activation, and binding proteins of TGF-. Microsc Res Tech 2001;52:354-362.
28. Godár S, Horejsi V, Weidle UH et al. M6P/IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-ß1. Eur J Immunol 1999;29:1004-1013.
29. Blakytny R, Ludlow A, Martin GE et al. Latent TGF-β1 activation by platelets. J Cell Physiol 2004;199:67-76.
30. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-1. Mol Endocrinol 1996;10:1077-1083.
31. Annes JP, Munger JS, Rifkin DB. Making sense of latent TGF activation. J Cell Sci 2003;116:217-224.
32. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-β. Microbes Infect 1999;1:1275-1282.
33. Boyd F, Massagué J. Transforming growth factor-inhibition of epithelial cell proliferation linked to the expression of a 53-kDa membrane receptor. J Biol Chem 1989;264:2272-2278.
34. Hakenjos L, Bamberg M, Rodemann H. TGF-ß1-mediated alterations of rat lung fibroblast differentiation resulting in the radiation-induced fibrotic phenotype. Int J Radiat Biol 2000;76:503-509.
35. Fajardo LF, Prionas SD, Kwan HH et al. Transforming growth factor 1 induces angiogenesis in vivo with a threshold pattern. Lab Invest 1996; 74:600-608.
36. Phillips GD, Whitehead RA, Stone AM et al. Transforming growth factor beta (TGF-B) stimulation of angiogenesis: An electron microscopic study. J Submicroscop Cytol Pathol 1993;25:149-155.
37. Roberts AB, McCune BK, Sporn MB. TGF regulation of extracellular matrix. Kidney Int 1992;41:557-559.
38. Peters H, Border WA, Noble NA. Targeting TGF-β overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade. Kidney Int 1998;54:1570-1580.
39. Border WA, Ruoslahti E. Transforming growth factor-β in disease: The dark side of tissue repair. J Clin Invest 1992;90:1-7.
40. Bartram U, Speer CP. The role of transforming growth factor beta in lung development and disease. Chest 2004;125:754-765.
41. Anscher MS, Kong FM, Jirtle RL. The relevance of transforming growth factor beta 1 in pulmonary injury after radiation therapy. Lung Cancer 1998;19:109-120.
42. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 1996; 2:418-423.
43. Akagi Y, Isaka Y, Arai M et al. Inhibition of TGF-β1 expression by antisense oligonucleotides suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 1996;50:148-155.
44. Tsushima H, Kawata S, Tamura S et al. Reduced plasma transforming growth factor-ß1 levels in patients with chronic hepatitis C after interfer-on-therapy: Association with regression of hepatic fibrosis. J Hepatol 1999;30:1-7.
45. Border W, Okuda S, Languino LR et al. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346:371-374.
46. Rabbani ZN, Batinic-Haberle I, Anscher MS et al. Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int J Radiat Oncol Biol Phys 2007;67:573-580.
47. Rabbani ZN, Anscher MS, Zhang X et al. Soluble TGF type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. Int J Radiat Oncol Biol Phys 2003;57:563-572.
48. Rabbani ZN, Anscher MS, Golson ML et al. Overexpression of extracellular superoxide dismutase reduces severity of radiation-induced lung toxicity through downregulation of the TGF- signal transduction pathway. Int J Radiat Oncol Biol Phys 2003;57:S158-S159.
49. Nishioka A, Ogawa Y, Mima T et al. Histopathologic amelioration of fibroproliferative change in rat irradiated lung using soluble transforming growth factor-beta (TGF-) receptor mediated by adenoviral vector. Int J Radiat Oncol Biol Phys 2004;58:1235-1241.
50. Nakao A, Fujii M, Matsumura R et al. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest 1999;104:5-11.
51. Kang S, Rabbani Z, Folz R et al. Overexpression of extracellular superoxide dismutase protects mice from radiation induced lung injury. Int J Radiat Oncol Biol Phys 2002;54:78.
52. Giri SN, Hyde DM, Hollinger MA. Effect of antibody to transforming growth factor ß on bleomycin induced accumulation of lung collagen in mice. Thorax 1993;48:959-966.
53. Daniels CE, Wilkes MC, Edens M et al. Imatinib mesylate inhibits the pro-fibrogenic activity of TGF- and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-1316.
54. Anscher MS, Crocker IR, Jirtle RL. Transforming growth factor-beta 1 expression in irradiated liver. Radiat Res 1990;122:77-85.
55. Franko AJ, Sharplin J, Ghahary A et al. Immunohistochemical localization of transforming growth factor beta and tumor necrosis factor alpha in the lungs of fibrosis-prone and "non-fibrosing" mice during the latent period and early phase after irradiation. Radiat Res 1997;147:245-256.
56. Liguang C, Larrier N, Rabbani ZN et al. Assessment of the protective effect of keratinocyte growth factor on radiation-induced pulmonary toxicity in rats. Int J Radiat Oncol Biol Phys 2003;57:S162.
57. Andarawewa KL, Paupert J, Pal A et al. New rationales for using TGF inhibitors in radiotherapy. Int J Radiat Biol 2007;83:803-811.
58. Portess DI, Bauer G, Hill MA et al. Low-dose irradiation of nontransformed cells stimulates the selective removal of precancerous cells via intercellular induction of apoptosis. Cancer Res 2007;67:1246-1253.
59. Flanders KC, Sullivan CD, Fujii M et al. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002;160:1057-1068.
60. Peters CA, Stock RG, Cesaretti JA et al. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;70: 752-759.
61. Anscher MS, Peters WP, Reisenbichler H et al. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328: 1592-1598.
62. Kong FM, Anscher MS, Murase T et al. Elevated plasma transforming growth factor beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995;222:155-162.
63. Kong F-M, Anscher M, Xiong Z et al. Elevated circulating transforming growth factor 1 levels decreased after radiotherapy in patients with lung cancer, cervical cancer and Hodgkin's disease: A possible tumor marker. Int J Radiat Oncol Biol Phys 1995;32(suppl 1):239.
64. Novakova-Jiresova A, Van Gameren MM, Coppes RP et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. Radiother Oncol 2004;71:183-189.
65. De Jaeger K, Seppenwoolde Y, Kampinga HH et al. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;58:1378-1387.
66. Anscher MS, Kong FM, Andrews K et al. Plasma transforming growth factor 1 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 1998;41:1029-1035.
67. Anscher MS, Kong FM, Marks LB et al. Changes in plasma transforming growth factor beta during radiotherapy and the risk of symptomatic radiation-induced pneumonitis. Int J Radiat Oncol Biol Phys 1997;37:253-258.
68. Anscher MS, Murase T, Prescott DM et al. Changes in plasma TGF beta levels during pulmonary radiotherapy as a predictor of the risk of developing radiation pneumonitis. Int J Radiat Oncol Biol Phys 1994;30:671-676.
69. Kong FM, Ao X, Wang L et al. The use of blood biomarkers to predict radiation lung toxicity: A potential strategy to individualize thoracic radiation therapy. Cancer Control 2008;15:140-150.
70. Fu XL, Huang H, Bentel G et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta. Int J Radiat Oncol Biol Phys 2001;50:899-908.
71. Anscher MS, Marks LB, Shafman TD et al. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. J Clin Oncol 2001;19:3758-3765.
72. Anscher MS, Marks LB, Shafman TD et al. Risk of long-term complications after TGF-β1-guided very-high-dose thoracic radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:988-995.
73. Teicher BA. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Rev 2001;20:133-143.
74. Bierie B, Moses HL. Tumour microenvironment: TGF: The molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-520.
75. Beck C, Schreiber H, Rowley D. Role of TGF- in immune-evasion of cancer. Microsc Res Tech 2001;52:387-395.
76. Shariat SF, Kattan MW, Traxel E et al. Association of pre-and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. Clin Cancer Res 2004;10:1992-1999.
77. Shariat SF, Walz J, Roehrborn CG et al. Early postoperative plasma transforming growth factor-1 is a strong predictor of biochemical progression after radical prostatectomy. J Urol 2008;179:1593-1597.
78. Wikström P, Damber J, Bergh A. Role of transforming growth factor-1 in prostate cancer. Microsc Res Tech 2001;52:411-419.
79. Muraoka-Cook RS, Kurokawa H, Koh Y et al. Conditional overexpression of active transforming growth factor 1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 2004;64:9002-9011.
80. Muraoka RS, Dumont N, Ritter CA et al. Blockade of TGF- inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002;109:1551-1559.
81. Bandyopadhyay A, Agyin JK, Wang L et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006;66:6714-6721.
82. Teicher BA, Ikebe M, Ara G et al. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: Reversal by decorin. In Vivo 1997;11:463-472.
83. Teicher BA, Holden SA, Ara G et al. Transforming growth factor-beta in in vivo resistance. Cancer Chemother Pharmacol 1996;37:601-609.
84. Kong F, Anscher M, Sporn T et al. Loss of mannose 6-phosphate/insulinlike growth factor receptor (M6P/IGF2R) may lead to an elevated transforming growth factor 1 (TGF 1) in circulation. Presented at the 45th Annual Meeting of the Radiation Research Society, Providence, RI, May 3-7, 1997.
85. Dennis PA, Rifkin DB. Cellular activation of latent transforming growth factor ß requires binding to the cation-independent mannose 6-phosphate/ insulin-like growth factor type II receptor. Proc Natl Acad Sci U S A 1991; 88:580-584.
86. Anscher M, Kong F, Sporn T et al. Loss of a normally functioning mannose 6-phosphate/insulin-like growth factor 2 receptor may lead to an elevated plasma transforming growth factor ß1 level: Clinical implications. Presented at the 9th Lorne Cancer Conference, Victoria, Australia, February 13-16, 1997.
87. Wrana JL, Attisano L, Cárcamo J et al. TGF β signals through a heteromeric protein kinase receptor complex. Cell 1992;71:1003-1014.
88. Chen RH, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF- activities. Science 1993; 260:1335-1338.
89. Yang L, Tredget EE, Ghahary A. Activation of latent transforming growth factor-1 is induced by mannose 6-phosphate/insulin-like growth factor-II receptor. Wound Repair Regen 2000;8:538-546.
90. Hankins GR, De Souza AT, Bentley RC et al. M6P/IGF2 receptor: A candidate breast tumor suppressor gene. Oncogene 1996;12:2003-2009.
91. Dahms NM, Lobel P, Kornfeld S. Mannose-6 phosphate receptors and lysosomal enzyme targeting. J Biol Chem 1989;264:12115-12118.
92. Kong F, Pulford D, Bandera M, et al. M6P/IGF2R tumor suppressor gene is mutated in lung cancer. Proc Am Assoc Cancer Res 1999;40:733.
93. Kong FM, Anscher MS, Sporn TA et al. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2001;49:35-41.
94. Li Y-Q, Ballinger JR, Nordal RA et al. Hypoxia in radiation-induced blood-spinal cord barrier breakdown. Cancer Res 2001;61:3348-3354.
95. Vujaskovic Z, Anscher MS, Feng Q-F et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 2001;50:851-855.
96. Anscher MS, Thrasher B, Rabbani Z et al. Antitransforming growth factor-beta antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. Int J Radiat Oncol Biol Phys 2006;65:876-881.
97. Falanga V, Zhou L, Yufit T. Low oxygen tension stimulates collagen synthesis and COL1A1 transcription through the action of TGF-β1. J Cell Physiol 2002;191:42-50.
98. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000;58:2351-2366.
99. Westbury CB, Pearson A, Nerurkar A et al. Hypoxia can be detected in irradiated normal human tissue: A study using the hypoxic marker pimonidazole hydrochloride. Br J Radiol 2007;80:934-938.
100. Haydont V, Mathe D, Bourgier C et al. Induction of CTGF by TGF-β1 in normal and radiation enteritis human smooth muscle cells: Smad/Rho balance and therapeutic perspectives. Radiother Oncol 2005;76:219-225.
101. Haydont V, Riser BL, Aigueperse J et al. Specific signals involved in the long-term maintenance of radiation-induced fibrogenic differentiation: A role for CCN2 and low concentration of TGF-β1. Am J Physiol Cell Physiol 2008;294:C1332-C1341.
102. Anscher MS, Thrasher B, Zgonjanin L et al. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2008;71:829-837.
103. Riley PA. Free radicals in biology: Oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994;65:27-33.
104. Kang SK, Rabbani ZN, Folz RJ et al. Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2003;57:1056-1066.
105. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN et al. A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 2002;33:857-863.
106. Inomata S, Takahashi H, Nagata M et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-467.
107. Haston CK, Travis EL. Murine susceptibility to radiation-induced pulmonary fibrosis is influenced by a genetic factor implicated in susceptibility to bleomycin-induced pulmonary fibrosis. Cancer Res 1997;57:5286-5291.
108. Nethery DE, Moore BB, Minowada G et al. Expression of mutant human epidermal receptor 3 attenuates lung fibrosis and improves survival in mice. J Appl Physiol 2005;99:298-307.
109. Faress JA, Nethery DE, Kern EF et al. Bleomycin-induced pulmonary fibrosis is attenuated by a monoclonal antibody targeting HER2. J Appl Physiol 2007;103:2077-2083.
110. Cho HJ, Kang JH, Kim T et al. Suppression of PAI-1 expression through inhibition of the EGFR-mediated signaling cascade in rat kidney fibro-blast by ascofuranone. J Cell Biochem 2009;107:335-344.
111. Wang Q, Wang Y, Hyde DM et al. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters. Thorax 1999;54:805-812.
112. Kolb M, Margetts PJ, Galt T et al. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am J Respir Crit Care Med 2001;163:770-777.
113. Stone HB, Coleman CN, Anscher MS et al. Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncol 2003;4:529-536.
114. Koli K, Myllärniemi M, Keski-Oja J et al. Transforming growth factor-beta activation in the lung: Focus on fibrosis and reactive oxygen species. Antioxid Redox Signal 2008;10:333-342.